Skip to content

EBITDA at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$125.93M+12.4%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.62M+2.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$98.33M+16.9%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$907.23M+54.1%
Enterprise value$898.76M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Calculated from Sana Biotechnology’s reported figures.

$48.6Mebit+
$2.4MDepreciation Depletion & Amortization
=-$46.22M

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's EBITDA?
Sana Biotechnology (SANA) reported EBITDA of -$46.22M in Q1 2026.
How has Sana Biotechnology's EBITDA changed year-over-year?
Sana Biotechnology's EBITDA increased by 1.6% year-over-year, from -$46.98M to -$46.22M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.